Rona Therapeutics, a Shanghai, China-based clinical stage platform company which specializes in nucleic acid drug research and development, raised $35M in Series A+ funding.
The round was led by LongRiver Investments with participation from new and existing global investment funds
The company intends to use the funds to progress metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery platform in CNS and beyond.
Led by CEO and Founder Ms. Stella SHI, Rona Therapeutics is a nucleic acid innovative drug platform company, specializing in the treatment of metabolic diseases and CNS degenerative diseases. Rona is advancing a pipeline of siRNA programs generated from next generation siRNA platform. The company’s first program RN0191, a best-in-class PCSK9 siRNA program, has completed Australia and China Ph1 clinical studies and ready for Ph2 clinical development for hypercholesterolemia. RN0361 is the company’s second program to enter clinic in 2024Q2 for hypertriglyceridemia. Rona is also advancing innovative pipeline at IND enabling stage for kidney disease, obesity and cardiometabolic diseases.
FinSMEs
19/07/2024